The Food and Drug Administration has announced it will withdraw its order cancelling the drug manufacturing license of Cipla Pharma forthwith, following a ruling by the Bombay High Court.
The court had intervened in the regulatory dispute between the FDA and the pharmaceutical company, prompting the regulatory body to reverse its earlier decision. The FDA stated it will issue a fresh show cause notice to Cipla Pharma as part of its ongoing regulatory review.
The development comes amid ongoing tensions between regulatory authorities and pharmaceutical manufacturers in India, highlighting the judiciary’s role in overseeing administrative decisions affecting the healthcare sector.
Sources: Hindustan Times – India News, https://www.hindustantimes.com/india-news/now-you-are-going-overboard-after-bombay-high-court-rap-fda-withdraws-order-cancelling-license-of-cipla-pharma-101788001180131.html
Corrections
If you believe this article contains an error, contact Herald Express with the source URL and supporting evidence.
Story synopsis gathered from: Hindustan Times – India News — source
